]. A. Ivanova, B. Paul, O. Marchenko, G. Song, N. Patel et al., Nine-year change in statistical design, profile, and success rates of Phase II oncology trials, Journal of Biopharmaceutical Statistics, vol.69, issue.1, pp.141-149, 2016.
DOI : 10.1007/s11912-013-0303-y

X. Sun, P. Peng, and D. Tu, Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion, Contemporary Clinical Trials, vol.32, issue.1, pp.108-113, 2011.
DOI : 10.1016/j.cct.2010.09.009

L. D. Case and T. M. Morgan, Design of Phase II cancer trials evaluating survival probabilities, BMC Medical Research Methodology, vol.7, issue.1, 2003.
DOI : 10.1023/A:1009621009283

B. Huang, E. Talukder, and N. Thomas, Optimal Two-Stage Phase II Designs with Long-Term Endpoints, Statistics in Biopharmaceutical Research, vol.2, issue.1, pp.51-61, 2010.
DOI : 10.1198/sbr.2010.09001

J. Wu, Sample size calculation for the one-sample log-rank test, Pharmaceutical Statistics, vol.32, issue.1, pp.26-33, 2015.
DOI : 10.1016/j.cct.2010.09.009

M. Kwak and S. H. Jung, Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test, Statistics in Medicine, vol.5, issue.12, 2004.
DOI : 10.1177/1740774508091748
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4013236/pdf

J. Whitehead, One-stage and two-stage designs for phase II clinical trials with survival endpoints, Statistics in Medicine, vol.33, issue.22, pp.3830-3843, 2014.
DOI : 10.1002/sim.6196

D. Y. Lin, L. Shen, Z. Ying, and N. E. Breslow, Group Sequential Designs for Monitoring Survival Probabilities, Biometrics, vol.52, issue.3, pp.1033-1041, 1996.
DOI : 10.2307/2533064

D. M. Finkelstein, A. Muzikansky, and D. A. Schoenfeld, Comparing Survival of a Sample to That of a Standard Population, CancerSpectrum Knowledge Environment, vol.95, issue.19, pp.1434-1439, 2003.
DOI : 10.1093/jnci/djg052

R. F. Woolson, Rank Tests and a One-Sample Logrank Test for Comparing Observed Survival Data to a Standard Population, Biometrics, vol.37, issue.4, pp.687-696, 1981.
DOI : 10.2307/2530150

D. P. Harrington and T. R. Fleming, Counting Processes and Survival Analysis, 2011.

S. H. Jung and C. B. Series, Randomized Phase II Cancer Clinical Trials, 2013.

A. Tsiatis, Repeated Significance Testing for a General Class of Statistics Used in Censored Survival Analysis, Journal of the American Statistical Association, vol.1, issue.380, pp.855-861, 1982.
DOI : 10.1093/biomet/68.1.311

A. De-la-rochefordiere, M. Kamal, A. Floquet, L. Thomas, P. Petrow et al., PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ?? Cetuximab in Cervical Cancer Patients, PIK3CA pathway mutations predictive of poor response following standard radiochemotherapy ± cetuximab in cervical cancer patients, pp.2530-2537, 2015.
DOI : 10.1158/1078-0432.CCR-14-2368

M. Buyse, Randomized Designs for Early Trials of New Cancer Treatments???an Overview, Drug Information Journal, vol.31, issue.2, pp.387-396, 2000.
DOI : 10.2307/2529712

L. Rubinstein, J. Crowley, P. Ivy, M. Leblanc, and D. Sargent, Randomized Phase II Designs, Clinical Cancer Research, vol.15, issue.6, pp.1883-1890, 2009.
DOI : 10.1158/1078-0432.CCR-08-2031
URL : http://clincancerres.aacrjournals.org/content/clincanres/15/6/1883.full.pdf

L. Belin, A two-stage design for phase II trials with time-to-event endpoint using restricted follow-up, Contemporary Clinical Trials Communications, vol.8, pp.127-134, 2017.
DOI : 10.1016/j.conctc.2017.09.010
URL : https://hal.archives-ouvertes.fr/hal-01617425